Evotec announces second multi-target collaboration with UCB

Wednesday, 05. October 2011 07:29
Evotec AG /
Evotec announces second multi-target collaboration with UCB
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany -05 October 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a second multi year, multi
target integrated drug discovery collaboration with UCB in the field of
immunology.

As part of the collaboration, Evotec will apply their integrated drug discovery
expertise and technologies to identify interesting small molecules against a
selected number of targets. The molecules will be further optimised and
progressed through lead optimization to a pre-clinical candidate.

Evotec will receive research funding based on the resource allocated over the
projects and will be further rewarded on achieving the goals of the research
collaboration with early stage discovery, preclinical and clinical milestones.
In addition Evotec will receive royalties based on net sales of any approved
drugs from the collaboration.

Dr Werner Lanthaler, Chief Executive Officer at Evotec stated: "We are extremely
pleased that UCB has again selected Evotec to collaborate on this second
significant Drug Discovery Collaboration.  This integrated drug discovery deal
showcases our broad target class expertise coupled with our industry leading
platform.  We look forward to a fruitful collaboration with our scientific
colleagues and friends at UCB."

Dr Ismail Kola, President, UCB NewMedicines commented: "Evotec is the ideal
partner to provide the resource bandwidth and drug-hunting expertise to
complement our internal efforts to progress this strategically important
program."

No financial details are disclosed.

Contact Evotec AG:

Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com



Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.




--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


PDF of Press Release:
http://hugin.info/131215/R/1552237/478201.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1552237]
Related Links: Evotec SE, 
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.